Related Experiment Video
Updated: Jun 4, 2026
06:58
Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
Published on: June 25, 2016
20.2K
Eslicarbazepine Use During Breastfeeding: A Case Report
Reversat-Brulant Thais1, Moschetti Sophie1, Atzenhoffer Marina1
1Service Hospitalo-Universitaire de Pharmacotoxicologie, Hospices Civils de Lyon, France.
Summary
Eslicarbazepine acetate use during breastfeeding is not well-documented. This case study shows reassuring infant serum levels and no adverse events in two infants, suggesting breastfeeding may be possible under supervision.
Area of Science:
- Pharmacology and Toxicology
- Neonatal and Developmental Pediatrics
- Maternal-Fetal Medicine
Background:
- Limited data exist on eslicarbazepine acetate (ESL) use in lactating women, often leading to cessation of breastfeeding for epilepsy management.
- Eslicarbazepine acetate is an anti-seizure medication with scarce information regarding its safety during lactation.
Purpose of the Study:
- To assess the safety and infant exposure of eslicarbazepine acetate during breastfeeding.
- To provide preliminary data on eslicarbazepine levels in breastfed infants.
Main Methods:
- Case report of two successive infants breastfed by a mother with pharmacoresistant epilepsy on eslicarbazepine acetate monotherapy.
- Measurement of infant serum concentrations of eslicarbazepine to evaluate drug exposure via maternal milk.
Main Results:
- Infant serum eslicarbazepine levels were measured, representing 9.1% of maternal serum concentration in one infant.
- No adverse drug reactions were reported in either infant after 13 months of breastfeeding each.
Conclusions:
- Breastfeeding under clinical supervision may be considered for healthy, full-term infants of mothers on eslicarbazepine acetate monotherapy, given limited reassuring data.
- Parents should be informed about the scarcity of safety data and unknown long-term neurodevelopmental outcomes.
- Monitoring infant serum levels is advised in cases of unexplained adverse reactions.
Keywords:
breastfeedingbreastfeeding medicinedrug safetyepilepsyeslicarbazepine acetatelactationnewbornMore Related Videos
Related Concept Videos
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...